The meta-analysis indicated that there was no significant difference in the risk of HE between patients treated with G-CSF and those treated with SMT alone (RR = 0.64, 95% CI: 0.27–1.50, P = 0.30, I2 = 0%). The gene discussed is CSF3; the disease is hereditary elliptocytosis.